尽管季度亏损和内部股票销售,但OklO在2026年3月获得了美国核能关键批准,推进其反应堆和同位素项目. Oklo gained key U.S. nuclear approvals in March 2026, advancing its reactor and isotope projects despite a quarterly loss and insider stock sales.

欧克洛公司在2026年3月获得了关键的监管批准,包括美国能源部核安全设计协议用于其格罗夫斯同位素试验反应堆和核监督委员会对其子公司原子化学材料许可证,使医疗同位体生产成为可能. Oklo Inc. received key regulatory approvals in March 2026, including a U.S. Department of Energy Nuclear Safety Design Agreement for its Groves isotopes test reactor and a Nuclear Regulatory Commission materials license for its subsidiary Atomic Alchemy, enabling medical isotope production. 该公司还推进了其奥罗拉微型反应堆和A3F燃料设施的建设, 关键性目标为7月4日. The company also advanced construction on its Aurora microreactor and A3F fuel facility, with criticality targeted for July 4. 尽管2025年第四季度每股亏损27美分,但估计不足.Oklo报告了7.88亿美元的现金,并将其2026年的现金使用指导提高到8.0亿美元用于运营和3.5亿美元为4.5亿元投资. Despite a Q4 2025 loss of 27 cents per share—missing estimates—Oklo reported $788 million in cash and raised its 2026 cash use guidance to $80–100 million for operations and $350–450 million for investing. 机构所有权仍然高,为85.03%,尽管内部人士在三个月内出售了1.76亿美元的股票,引发了担忧. Institutional ownership remains high at 85.03%, though insiders sold $170–176 million in stock over three months, raising concerns. 该股票的交易价格为60.75美元,市值94.9亿美元,共识是"中等买入",目标价为91.47美元. The stock, trading at $60.75 with a $9.49 billion market cap, has a “Moderate Buy” consensus and a $91.47 price target.